Alembic submits ANDA for Bosutinib Monohydrate
Alembic has submitted an Abbreviated New Drug Application (ANDA) for Bosutinib Monohydrate.
Therapeutic Area
Therapeutic area intelligence for Tyrosine Kinase Inhibitor with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.